NCT00110864已完成2 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 36
- 主要终点
- Safety
研究概览
简要总结
This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will also be measured.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosed with type 2 diabetes mellitus
- •21 to 65 years of age
- •on stable doses of insulin (>/= 40 units/day) alone or with metformin for at least 3 months
- •HbA1c level of >/=7.5% but </=10.0%
- •fasting blood sugar level >/= 125 mg/dL but </= 279 mg/dL
- •BMI 26-43 kg/m2
- •direct bilirubin < 1.5x the upper limit of normal (ULN)
- •serum creatinine < 1.5 mg/dL (males) or < 1.4 mg/dL (females)
- •blood urea nitrogen (BUN)</=40 mg/dL
- •all other clinical laboratory parameters (hematology, serum chemistry, and urinalysis) within normal limits or not clinically significant
- •ECG normal, or abnormalities not clinically significant
- •surgically sterile,postmenopausal,or using adequate contraception and have a negative pregnancy test at Screening
- •able to perform daily self-monitoring of blood glucose (SMBG) tests
- •willing and able to sign an informed consent form
排除标准
- •diagnosed with type 1 diabetes mellitus or has a history of ketoacidosis
- •treatment with TZDs or any other oral antidiabetic (excluding metformin) within 3 months prior to screening or during study treatment
- •change in lipid-lowering medication within 2 months of screening
- •taken systemic corticosteroids within 1 month prior to screening or during study treatment
- •history of or current/active cardiovascular disease
- •significant current pulmonary conditions
- •significant thyroid disease
- •CPK value > 3x ULN
- •a female who is pregnant or lactating
- •systolic BP > 160 mm Hg or a diastolic BP > 90 mm Hg at screening
- •previous or current history of cancer, other than basal cell or stage 1 squamous cell carcinoma of the skin, that has not been in remission within 5 years prior to randomization
- •liver function tests (ALT, AST, ALP) > 2 times ULN, or active liver disease at screening
- •history of positive HIV
- •positive hepatitis B test at screening
- •weight loss or gain >/= 15 lbs within 3 months of screening
- •history of substance abuse (including alcohol abuse) within 2 years prior to screening
- •donated and/or received any blood or blood products within 3 months prior to randomization
- •taken an investigational study medication within 30 days prior to screening or during the study
结局指标
主要结局
Safety
Effect on change in average daily insulin dose
次要结局
- Effect on HbA1c levels
- Effect on FPG levels
- Effect on lipid levels
研究者
研究点 (36)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)Type 2 Diabetes MellitusNCT00110851Wellstat Therapeutics90
终止
2 期
A Study of LY2409021 in Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT02111096Eli Lilly and Company174
已完成
2 期
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT01475461Pfizer345
已完成
2 期
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes MellitusDiabetes Mellitus, Type IINCT02175121Pfizer172
已完成
2 期
A Study of LY2409021 in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01241448Eli Lilly and Company263